MYNZ
MYNZ
NASDAQ · Biotechnology

Mainz Biomed Nv

$1.37
+0.04 (+3.01%)
As of Sep 28, 10:42 PM ET ·
Financial Highlights (FY 2026)
Revenue
5.35M
Net Income
-129,553,183
Gross Margin
64.3%
Profit Margin
-2,421.8%
Rev Growth
+15.5%
D/E Ratio
0.37
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 64.3% 64.3% 39.8% 39.8%
Operating Margin -2,088.1% -1,879.3% -3.7% -3.3%
Profit Margin -2,421.8% -2,300.7% -3.2% -3.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 5.35M 4.63M 1.76M 1.56M
Gross Profit 3.44M 2.98M 701.2K 621.1K
Operating Income -111,696,781 -87,028,917 -65,674 -51,454
Net Income -129,553,183 -100,941,792 -56,960 -48,803
Gross Margin 64.3% 64.3% 39.8% 39.8%
Operating Margin -2,088.1% -1,879.3% -3.7% -3.3%
Profit Margin -2,421.8% -2,300.7% -3.2% -3.1%
Rev Growth +15.5% +15.5% +11.5% -6.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.03M 1.03M 1.22M 1.09M
Total Equity 2.79M 2.79M 4.09M 3.85M
D/E Ratio 0.37 0.37 0.30 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -117,080,536 -96,291,671 -70,729 -65,893
Free Cash Flow — — -37,098 -32,467